title: Safety and effectiveness of intravenous thrombolysis with recombinant tissue plasminogen activator in eighty years and older acute ischemic stroke patients.
abstract: OBJECTIVE
  To explore the safety and efficacy of intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) in elderly (≥ 80 years old) acute ischemic stroke (AIS) patients.
  
  
  METHODS
  The clinical data of patients who were treated in Tianjin Huanhu Hospital from June 2012 to November 2013 were retrospectively analyzed; amongst them 404 patients had received IVT with rt-PA and 200 patients had not received IVT. Among ≥ 80 years' old patients, 204 had received IVT and 200 had not. And, the 404 patients who had received IVT, they were divided into two subgroups: elderly (≥ 80 years of age; n = 204) and controls (< 80 years old; n = 200). The incidence of intracranial hemorrhage (ICH) and symptomatic intracranial hemorrhage (sICH), case-fatality rate, and other prognostic indicators were compared.
  
  
  RESULTS
  Among all ≥ 80 years' old patients, the IVT subgroup had significantly superior good outcome rates than the non-IVT subgroup at 24-h and 3-month, along with significantly lower case-fatality rate. But for the patients those who had received IVT, the incidence of ICH and the 7-day case-fatality rate were not significantly increased in both the elderly and control subgroups. The 24-h and 3-month good outcome rates were not significantly different between these two subgroups as well.
  
  
  CONCLUSIONS
  IVT with rt-PA is a safe and effective treatment for ≥ 80 year's old AIS patients.
authors.affiliation: Department of Neurology, Tianjin Huanhu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China. peilanzhng@sina.com.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.forename: C-H
authors.initials: CH
authors.lastname: Li
authors.forename: Y-X
authors.initials: YX
authors.lastname: Wang
authors.forename: C-H
authors.initials: CH
authors.lastname: Zhang
authors.forename: Z
authors.initials: Z
authors.lastname: Dong
authors.forename: F-F
authors.initials: FF
authors.lastname: Zhang
authors.forename: J-H
authors.initials: JH
authors.lastname: Wang
authors.forename: P-L
authors.initials: PL
authors.lastname: Zhang
mesh_terms: D061605:Administration, Intravenous; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000175:diagnosis* / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D020521:Stroke / Q000175:diagnosis* / Q000188:drug therapy*; D015912:Thrombolytic Therapy / Q000009:adverse effects; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator